| Recruiting | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma Hodgkin Lymphoma, Hodgkin Disease, Advanced Hodgkin Lymphoma | Phase 2 | 2025-07-29 |
| Not Yet Recruiting | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell L Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | — | 2025-01-09 |
| Completed | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-ce Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | 2024-11-26 |
| Recruiting | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML Refractory Acute Myeloid Leukemia, Early Relapses of Acute Myeloid Leukemia | Phase 3 | 2024-04-01 |
| Recruiting | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Precursor Cell Lymphoblastic Leukemia-Lymphoma | N/A | 2023-04-01 |
| Recruiting | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo- Primary Mediastinal Lymphoma | Phase 3 | 2022-04-01 |
| Unknown | Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction | Phase 3 | 2022-01-01 |
| Completed | Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccinat SARS-CoV-2 Infection, SARS-CoV-2 Vaccination | — | 2021-07-07 |
| Recruiting | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagno Primary CNS Lymphoma | Phase 2 | 2021-05-17 |
| Unknown | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remiss AML | N/A | 2021-02-01 |
| Completed | Registry of Patients With Hematologic Disease and COVID-19 in Russia Coronavirus Infection and Hematologic Diseases | — | 2020-06-22 |
| Unknown | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia | Phase 2 | 2020-01-15 |
| Unknown | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, V Hodgkin Lymphoma | Phase 2 | 2019-08-19 |
| Unknown | De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) Precursor Cell Lymphoblastic Leukemia-Lymphoma | N/A | 2017-01-01 |
| Unknown | Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT Mesenchymal Stem Cell Transplantation | Phase 3 | 2017-01-01 |
| Unknown | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Diffuse Large B-Cell Lymphoma | Phase 3 | 2015-02-01 |
| Unknown | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Leukemia, Multiple Myeloma | Phase 2 / Phase 3 | 2014-01-01 |
| Unknown | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituxi Follicular Lymphoma | Phase 3 | 2013-12-01 |
| Unknown | Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients | Phase 1 / Phase 2 | 2012-12-01 |
| Unknown | 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid L Acute Myeloid Leukemia | Phase 4 | 2010-01-01 |
| Unknown | Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment Ph-negative Adult Acute Lymphoblastic Leukemia | N/A | 2008-11-01 |
| Unknown | Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Graft-versus-host Disease, Relapse | Phase 2 | 2007-10-01 |